1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Compliance

DOJ: Medical Supply Firms Can Collaborate During COVID-19 Crisis

 
• By Elizabeth Orr

Medical supplies manufacturers can collaborate to address the novel coronavirus pandemic without violating antitrust law, the US Department of Justice has said.

Washington DC - Department of Justice Building

Medical supply companies won’t violate anti-trust law by collaborating to address the COVID-19 public health crisis, the US Department of Justice (DOJ) said in a 4 April letter to manufacturers.

The letter, which is signed by assistant attorney general Makan Delrahim, was sent to supply makers McKesson Corp., Owens & Minor Inc., Cardinal Health Inc., Medline Industries Inc. and Henry Schein Inc.. They are working together as part of the government’s Project Airlift initiative to quickly source and deliver personal protective equipment (PPE), including masks, gowns and gloves to areas of greatest need across the country

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

Don’t Sleep On Inspections: Experts Warn FDA Maintains Enforcement Resources

 
• By Brian Bossetta

Manufacturers of medical products would be foolish to think that recent upheavals at the US FDA will result in a lack of inspections in the coming years. A panel of experts discussed the current state of inspections during a webinar hosted by the Food and Drug Law Institute.

Global Medtech Guidance Tracker: April 2025

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. 25 documents have been posted on the tracker since its last update.

New Guidance From Canada’s HTA Agency On Submission Of AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 
• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

More from Policy & Regulation